All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...

Argenx (NASDAQ: ARGX) has been upgraded to an "outperform" rating from "underperform" by Bernstein, with the price target revised sharply upwards to €755 from 1 ...

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of its ambulatory infusion suite (AIS) in Fort Wayne, further expanding its ...

AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated ...

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...

Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating ...

AstraZeneca and Ionis’ Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary ...